

座談会

〈Round table discussion〉

## 第2回ネグレクトド・ディジーズ のための新薬開発座談会 研究室から患者のもとへ — 成果と課題\*1

Part 1 ネグレクトド・ディジーズ治療のためのパートナーシップ：  
2005年から2018年までの13年間の変化を辿る

Part 2 日本におけるグローバルヘルスの実現に向けた開発の進歩と課題：  
変革への提言

Simon L Croft\*2 (Professor, Faculty of Infectious and Tropical Diseases,  
London School of Hygiene & Tropical Medicine)

山田 陽城\*3 (特定非営利活動法人DNDi Japan 理事長)

北 潔\*4 (長崎大学大学院熱帯医学・グローバルヘルス研究科長)

Chris Brünger\*5 (IDEC Inc. CEO)

平林 史子\*6 (特定非営利活動法人DNDi Japan 理事)

井本 大介 (特定非営利活動法人DNDi Japan 事務局代表)

リライト・訳 (Part 1) 平林 史子\*6

企画・構成 栗原千絵子\*7, 齊尾 武郎\*8

(2018年5月12日(土) 於：IDEC Inc.会議室, 東京)

### The 2<sup>nd</sup> round table discussion on development of new medicines for neglected tropical diseases: From bench to bed, achievements and challenges

Part 1 Partnerships, treatments and NTDs: 2005 to 2018, 13 years of change

Part 2 Progress and challenges of development towards global health:  
Proposals for revolution

Simon L Croft\*2 (Professor, Faculty of Infectious and Tropical Diseases,  
London School of Hygiene & Tropical Medicine)

Haruki Yamada\*3 (Chair, DNDi Japan)

Kiyoshi Kita\*4 (Dean, School of Tropical Medicine and Global Health, Nagasaki University)

Chris Brünger\*5 (CEO, IDEC Inc.)

Fumiko Hirabayashi\*6 (Board member, DNDi Japan)

Daisuke Imoto (Head of Office, DNDi Japan)

Dictation and translation by: Fumiko Hirabayashi\*6

Organized by: Chieko Kurihara\*7, Takeo Saio\*8

(Saturday, May 12, 2018, IDEC Inc. conference room, Tokyo, Japan)

\*1 本座談会は、Part 1はSimon L Croft氏のプレゼンテーションを主として英語で、Part 2は主として日本語で行われた上、概要がCroft氏に英語で伝達され、英語での発言の和訳と、日本語での発言の採録より構成されている。Croft氏のプレゼンテーションと質疑のみの英語版は本誌ホームページ [http://cont.o.oo7.jp/46\\_2/46\\_2contents.html](http://cont.o.oo7.jp/46_2/46_2contents.html) に掲載。

## Abstract

Just a little over a decade ago, research and development (R&D) for neglected diseases was stagnant. Since then, neglected tropical diseases (NTDs) have been defined, product development partnerships (PDPs) have been established, and private and academic sectors have been mobilized to work together. This has brought about a huge movement that has grown around NTDs. PDPs have acted as an effective catalyst in encouraging Pharma and academia to engage in these diseases, various forms of innovative public private partnerships have been developed, and new treatments are in the pipeline.

Much has been achieved over the past 13 years, but we have still got work to do. Sustaining not just the funding but sustaining the expertise is a real issue. Involving disease endemic countries in drug R&D is also an important challenge. PDPs, government, Pharma, academia will all remain responsible for ensuring that developed drugs are used effectively in the settings of poverty or broken health systems. All drugs created and approved need nurturing.

In the middle of these huge changes globally, Japan has demonstrated great potential with its government's commitment and the dedicated efforts by top-level scientists. As global R&D into NTDs and other neglected diseases is advancing, increased efforts are needed to secure funding for further innovation, ensure effective use of developed drugs, and promote partnership-based R&D models. Japan is expected to continue making significant contributions as one of the key players.

## Key words

product development partnerships (PDPs), neglected tropical diseases (NTDs), research funding, research and development (R&D), innovation

*Rinsho Hyoka (Clinical Evaluation)*. 2018 ; 46 : 197-235.

---

\*2 元DNDi研究開発本部長, 現DNDi科学諮問委員会委員 (Member, Scientific Advisory Committee, Drugs for Neglected Diseases *initiative* (DNDi); Former Director, R&D (Research and Development), DNDi)

\*3 北里大学名誉教授, 元DNDi科学諮問委員会委員 (Emeritus Professor, Kitasato University; Former Member, Scientific Advisory Committee, Drugs for Neglected Diseases *initiative* (DNDi))

\*4 東京大学名誉教授, 現DNDi科学諮問委員会委員 (Emeritus Professor, The University of Tokyo; Member, Scientific Advisory Committee, Drugs for Neglected Diseases *initiative* (DNDi))

\*5 元DNDiコンサルタント, 元DNDi科学諮問委員会委員 (Former Consultant, Drugs for Neglected Diseases *initiative* (DNDi); Former Member, Scientific Advisory Committee, DNDi)

\*6 元DNDi日本代表, 元特定非営利活動法人DNDi Japan事務局長 (Former Japan Representative, Drugs for Neglected Diseases *initiative* (DNDi); Former Head of Office, DNDi Japan)

\*7 国立研究開発法人量子科学技術研究開発機構放射線医学総合研究所, 「臨床評価」編集委員 (National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology; Editor, *Clinical Evaluation*)

\*8 フジ虎ノ門整形外科病院内科・精神科, 「臨床評価」編集協力者 (Department of Internal Medicine and Psychiatry, Fuji Toranomon Orthopedic Hospital; Collaborator to the *Clinical Evaluation* Editorial Committee)